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ORIGINAL ARTICLE
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ABSTRACT
Purpose: Report global adalimumab safety and efﬁcacy outcomes in patients with non-infectious uveitis.
Methods: Adults with non-infectious intermediate, posterior, or panuveitis were randomized 1:1 to receive
placebo or adalimumab in the VISUAL I (active uveitis) or VISUAL II (inactive uveitis) trials. Integrated global
and Japan substudy results are reported. The primary endpoint was time to treatment failure (TF).
Results: In the integrated studies, TF risk was signiﬁcantly reduced (hazard ratio [95% CI]) with adalimumab
versus placebo (VISUAL I: HR = 0.56 [0.40–0.76], p < 0.001; VISUAL II: HR = 0.52 [0.37–0.74], p < 0.001). In Japan
substudies, no consistent trends were observed between groups (VISUAL I: HR = 1.20 [0.41–3.54]; VISUAL II:
HR = 0.45 [0.20–1.03]). Adverse event rates were similar between treatment groups in both studies (854 to 1063
events/100 participant-years).
Conclusions: Adalimumab lowered time to TF versus placebo in the integrated population; no consistent trends
were observed in Japan substudies. Safety results were consistent between studies.
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Uveitis is a heterogeneous collection of diseases with
varied genetic and environmental inﬂuences. It has
been estimated that uveitis accounts for about 10% of
the visual handicap in the Western world, and up to
35% of all patients with uveitis suffer substantial
visual impairment or legal blindness.1 The annual pre-
valence of uveitis in the general population is esti-
mated at 115–204 per 100,000 population, and the
incidence is estimated at 17–52 per 100,000
population.2 As uveitis often affects the young adult
population in their most productive years of life, the
personal and population burden of this sight-threaten-
ing disease is noteworthy.3,4 Conventional therapy
with corticosteroids (CS) has been the mainstay to
treat uveitis; although CS are often effective, ocular
and/or systemic adverse effects limit their long-term
use.5–7
Adalimumab (Humira®; AbbVie Inc., North
Chicago, IL) is a recombinant human immunoglobu-
lin (IgG1) monoclonal antibody that binds speciﬁ-
cally to tumor necrosis factor (TNF) and neutralizes
its biological function.8–11 Adalimumab’s safety and
efﬁcacy proﬁle spans over 13 years for various
approved inﬂammatory conditions.12 Recently, ada-
limumab received approvals from the US Food and
Drug Administration (FDA), European Medicines
Agency (EMA), and Japan Pharmaceutical and
Medical Devices Agency (PMDA) to treat adult par-
ticipants with non-infectious intermediate, posterior,
and panuveitis.
It is critical to prevent inﬂammation and vision
loss in eyes with uveitis. The VISUAL I and
VISUAL II studies were randomized, double-
masked, placebo-controlled clinical trials designed
to assess the efﬁcacy and safety of adalimumab in
inducing quiescence along with CS and maintaining
the achieved quiescence in participants with active
uveitis (VISUAL I) and as a steroid-sparing agent
preventing relapse in participants dependent on CS
to maintain inactivity (VISUAL II). The VISUAL
program demonstrated adalimumab’s ability to
lower the risk of uveitic recurrence and visual
acuity loss in participants with active (VISUAL I)
and an inactive disease state (VISUAL II) uveitis.-
13,14 The VISUAL program is the ﬁrst successful
program where the treatment effect of a non-CS
medication could be demonstrated in two separate
randomized controlled trials in non-infectious uvei-
tis populations.
Due to regional heterogeneity and in agreement
with the Japan PMDA, separate Japan substudies
were conducted for the Japanese study participants.
These substudies enrolled Japanese participants
under a separate stratum to demonstrate direction-
ality of substudy results when compared with those
of the main studies. Results from the Japan substu-
dies in context with the global integrated study
results (main study and Japan substudy) from the
VISUAL I and VISUAL II trials are reported.
METHODS
Study Design and Oversight
VISUAL I and VISUAL II were phase 3, randomized,
double-masked, placebo-controlled studies conducted
in 22 countries involving 74 and 72 study sites, respec-
tively, between August 2010 and May 2015
(ClinicalTrials.gov identiﬁers, VISUAL I: NCT01138657
and VISUAL II: NCT01124838; registered May 2010).
The study protocols were approved by the responsible
ethics committees and internal review boards, and stu-
dies were performed in compliance with the Declaration
of Helsinki, Good Clinical Practice (GCP) guidelines,
and applicable local regulations.
For VISUAL I, the Japan substudy was to end when
either the 138th event of treatment failure had
occurred in the VISUAL I main study or when the
19th event of treatment failure had occurred in the
VISUAL I Japan substudy. For VISUAL II, the Japan
substudy was to end when either the 96th event of
treatment failure had occurred in the VISUAL II main
study or when the 17th event of treatment failure had
occurred in the VISUAL II Japan substudy.
Study Participants
VISUAL I
Participants (aged ≥ 18 years) with active non-infec-
tious intermediate, posterior, or panuveitis were
enrolled. Key inclusion criteria were active disease
(active inﬂammatory chorioretinal or retinal vascular
lesions, anterior chamber [AC] cell grade ≥ 2+, and/or
vitreous haze [VH] grade ≥ 2+) and use of oral pre-
dnisone (≥ 10 mg/day to ≤ 60 mg/day) or a CS equiva-
lent for ≥ 2 weeks before screening. Participants with
isolated anterior uveitis or infectious uveitis, prior
inadequate response to high-dose oral CS, or any ocu-
lar or systemic condition that would preclude safe
participation in the study or interfere with study
assessments were excluded.
VISUAL II
Participants (aged ≥ 18 years) with inactive non-
infectious intermediate, posterior, or panuveitis
were enrolled. Key inclusion criteria were inactive
disease ≥ 28 days prior to the baseline visit and
daily oral prednisone ≥ 10 to ≤ 35 mg to maintain
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inactive uveitis. Inactive uveitis was deﬁned as no
active inﬂammatory chorioretinal and/or retinal vas-
cular lesions, AC cell grade ≤ 0.5+, and/or VH grade
≤ 0.5 +. To demonstrate CS dependency, the partici-
pant should have had a documented history of
experiencing at least 1 disease ﬂare during or within
28 days of tapering steroids, within 18 months of the
screening visit. Participants with isolated anterior or
infectious uveitis or any condition precluding safe
participation in the study or interfering with study
assessments were excluded.
Randomization and Study Treatments
For the main studies, at the baseline visit participants
were randomized to placebo or adalimumab treatment
groups in a 1:1 ratio stratiﬁed by baseline immunosup-
pressant use with an interactive voice/web response
system that assigned allocation numbers and treat-
ments. Japanese participants were randomized in a
separate stratum and due to the small sample size in
the Japan substudies no stratiﬁcation by baseline immu-
nosuppressant use was performed. Adalimumab and
placebo were supplied in pre-ﬁlled syringes and were
administered subcutaneously. The adalimumab group
received an 80-mg baseline loading dose followed by
40-mg doses every other week starting at week 1 for the
duration of the study. For VISUAL I, all participants
received a standardized, 60 mg/day prednisone burst
at study entry followed by a mandatory prednisone
taper to 0 mg by week 15. For VISUAL II, participants
were on 10 to 35 mg/day of oral prednisone at baseline
and from week 2, all participants underwent a manda-
tory prednisone taper to 0 mg by week 19. In both
studies, topical steroids were allowed at study entry,
but participants were to undergo mandatory taper from
week 1 to week 9.
Study Visits and Endpoints
Clinic visits were scheduled at screening; baseline; week
1 (VISUAL I), week 2 (VISUAL II), week 4, and approxi-
mately every 4 weeks thereafter. Participants were
assessed until treatment failure was determined or com-
pletion of the 80-week study. Participants were assessed
for treatment failure starting at week 6 for VISUAL I and
week 2 for VISUAL II (Table 1). The primary efﬁcacy
endpoint and ranked secondary endpoints were tested
and are listed in Table 2.
Adalimumab immunogenicity was evaluated at
multiple time points throughout the study. Adverse
events (AEs) were monitored throughout the study
and reported from the ﬁrst dose of study drug until
70 days after the last dose of study drug or until
participants were rolled into a separate extension
study. Serious AEs were collected from the time of
informed consent. AEs were tabulated using Medical
Dictionary for Regulatory Activities (MedDRA) ver-
sion 17.0 system organ class and preferred terms.
Procedures
Presence or absence of inﬂammatory chorioretinal and/
or retinal vascular lesions and VH grade were deter-
mined by dilated indirect ophthalmoscopy, and AC cell
counts were assessed using slit-lamp biomicroscopy and
graded using Standardization of Uveitis Nomenclature
(SUN)-adapted National Eye Institute (NEI) criteria.15,16
Statistical Analysis for VISUAL I and VISUAL II
Efﬁcacy endpoints were analyzed in the intent-to-treat
(ITT) data set (all participants randomized to treat-
ment, excluding six participants from two non-compli-
TABLE 1. Criteria for treatment failure for VISUAL I and VISUAL II clinical trials.
Treatment Failure Parameters*
VISUAL I VISUAL II
Week 6 All other visits after week 6 At or after week 2
Inﬂammatory, chorioretinal and/or
inﬂammatory retinal vascular
lesions
New active, inﬂammatory
lesions relative to baseline
New active, inﬂammatory
lesions relative to baseline
New active, inﬂammatory
lesions relative to baseline
Anterior chamber cell grade (SUN
criteria)
Inability to achieve ≤0.5+ 2-step increase relative to best
state achieved†
2-step increase relative to
baseline†
Vitreous haze grade (NEI/SUN
criteria)
Inability to achieve ≤0.5+ 2-step increase relative to best
state achieved†
2-step increase relative to
baseline†
Visual acuity (ETDRS) Worsening of BCVA by ≥15
letters relative to best state
achieved
Worsening of BCVA by ≥15
letters relative to best state
achieved
Worsening of BCVA by ≥15
letters relative to baseline
BCVA = best corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; NEI = National Eye Institute;
SUN = Standardization of Uveitis Nomenclature.
*Treatment failure deﬁned as ≥1 of the 4 criteria in ≥1 eye.
†A 2-step increase was represented by a change of grade 0 to grade 2+; or grade 0.5+ to grade 3+.
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ant sites in VISUAL I and three participants from two
non-compliant sites in VISUAL II).
Time to treatment failure was compared between
treatment groups using a log-rank test. A proportional
hazards model was ﬁtted to estimate the hazard ratio
(HR) with its 95% conﬁdence interval (CI). Ranked sec-
ondary endpoint changes in AC cell grade, VH grade,
and best corrected visual acuity (BCVA) were compared
between groups by analysis of variance with treatment
as factor adjusted for clustered observations within a
participant. For analysis of secondary variables, missing
data were imputed using last observation carried
forward.
Testing of the primary and ranked secondary end-
points was conducted at a two-sided signiﬁcance level of
5% in hierarchical order. In case of a non-signiﬁcant test,
the conﬁrmatory multiple test procedure was stopped
and p-values of secondary endpoints further down in
the hierarchy were considered exploratory and descrip-
tive in nature.
Participant information was summarized using
descriptive statistics, continuous variableswere compared
by analysis of variance, and discrete variables were ana-
lyzed using chi-square tests or Fisher’s exact test.
Treatment-emergent AEs were summarized descriptively
by treatment group. AEswere presented as events per 100
participant-years (100 PY) to avoid confounding by
between-group differences in duration of exposure to
study treatment. Analyses were performed by the study
sponsor using SAS software (SAS Institute Inc., Cary,
NC). Data reported here reﬂect ﬁnal study data.
RESULTS
Participants
VISUAL I
Of 239 participants randomized to treatment, 233 (217
main study and 16 Japan substudy) participants were
included in the ITT analyses (six participants were
excluded from non-compliant sites; placebo, n = 115
and adalimumab, n = 118). Most participants were
female (58%) and white (75%); 47% were diagnosed
with panuveitis. Mean participant age was 43.2 years,
and mean duration of uveitis was 46 months. There
were no signiﬁcant differences between randomized
groups in demographics and baseline characteristics
(Table 3). Seven participants receiving placebo and 18
receiving adalimumab discontinued the study. AEs
were the most common reason for discontinuation in
both treatment groups (Figure 1A). The majority of the
participants in the Japan substudy were diagnosed with
panuveitis (13/16 [81.3%]), including all participants in
the placebo group, compared with 97/217 (44.7%) in the
main study. The three participants without panuveitis in
the Japan substudy were in the adalimumab group and
were diagnosed with intermediate (n = 1) or posterior
uveitis (n = 2). Seven participants in the Japan substudy
were diagnosed with idiopathic uveitis (placebo, n = 4;
adalimumab, n = 3); one participant in the substudy
receiving adalimumab was diagnosed with Vogt
Koyanagi Harada disease; six participants (placebo,
n = 4; adalimumab, n = 2) were diagnosed with sarcoi-
dosis; and two participants receiving adalimumab were
diagnosed with Behçet’s disease (Table 3).
VISUAL II
Of 261 participants randomized to treatment, 258 (226
main study and 32 Japan substudy) participants were
included in the ITT analyses (three participants were
excluded fromnon-compliant sites) (placebo, n= 127; ada-
limumab, n = 131). More participants were female (61%)
and white (73%); 51% were diagnosed with panuveitis.
Mean participant age was 43.1 years, and mean duration
of uveitis was 59months. Therewere no signiﬁcant differ-
ences between randomized groups in demographics and
baseline characteristics (Table 3). Seventeen participants
receiving placebo and 15 receiving adalimumab discon-
tinued the study. AEs were the most common reason for
discontinuation in both treatment groups (Figure 1B). The
majority of the participants in the Japan substudy were
diagnosed with panuveitis (29/32 [90.6%]), compared
with 103/226 (45.6%) in the main study. Three partici-
pants in the Japan substudy were diagnosed with poster-
ior uveitis (placebo, n = 1; adalimumab, n = 2). Eight
participants in the substudy were diagnosed with idio-
pathic uveitis (placebo, n = 4; adalimumab, n = 4); 12
participants were diagnosed with Vogt Koyanagi
Harada disease (placebo, n = 4; adalimumab, n = 8); 10
participants were diagnosed with sarcoidosis (placebo,
n = 6; adalimumab, n = 4); and one participant in the
placebo group was diagnosed with Behçet’s disease
(Table 3).
Efﬁcacy
VISUAL I
Median time to treatment failure was signiﬁcantly dif-
ferent between the placebo (3 months) and adalimumab
TABLE 2. Primary endpoint and ranked secondary endpoints
for VISUAL I and VISUAL II trials.
A) Primary Endpoint
Time to treatment failure
B) Ranked Secondary Endpoints*
1 Change in AC cell grade in each eye
2 Change in VH grade in each eye
3 Change in BCVA (logMAR) in each eye
AC = anterior chamber; BCVA = best corrected visual acuity;
VH = vitreous haze.
*Data reﬂect change from best state achieved prior to week 6
to the ﬁnal/early termination visit for VISUAL I and change
from baseline to ﬁnal/early termination visit for VISUAL II.
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(4.8 months) groups for the integrated study. The risk of
treatment failure for participants in the adalimumab
group was reduced by 44% compared with participants
in the placebo group (HR = 0.56; 95% CI, 0.40–0.76;
p < 0.001). In the Japan substudy, time to treatment
failure was shorter (placebo, 2.8 months and adalimu-
mab, 2.4 months) than the non-Japanese (main study)
participants, and did not show a clear difference
between the adalimumab group and placebo group
(HR = 1.20; 95% CI, 0.41–3.54). In the Japan substudy
there was one outlier participant in the placebo group
who did not meet treatment failure and strongly
impacted the outcome of the primary endpoint, given
the small number of participants in the substudy. The
HR (95% CI) in the Japan substudy for the primary
endpoint was 0.73 (0.22–2.40) when this participant
was excluded (Table 4).
Hierarchical testing of the ranked secondary out-
comes showed that worsening of AC cell grade, VH
grade, and BCVA were signiﬁcantly reduced in par-
ticipants receiving adalimumab versus placebo
(p < 0.05). The Japan substudy had similar
directionality as the main study after excluding the
outlier participant, except for AC cell grade
(Table 5).
VISUAL II
Similar to results in VISUAL I, there was a robust
and statistically signiﬁcant difference between adali-
mumab and placebo groups in the VISUAL II inte-
grated study. Median time to treatment failure was
5.6 months for placebo and not estimable
(> 18 months) for adalimumab, as more than half
of the adalimumab-treated participants did not
experience treatment failure for the integrated
study. The risk of treatment failure for participants
in the adalimumab group was reduced by 48% com-
pared with participants in the placebo group
(HR = 0.52; 95% CI, 0.37–0.74; p < 0.001). In the
Japan substudy, time to treatment failure (placebo,
2.1 months and adalimumab, 2.9 months) had simi-
lar directionality as in the main study, with adali-
mumab reducing the risk of treatment failure
(HR = 0.45; 95% CI, 0.20–1.03; Table 4).
FIGURE 1. Participant disposition. VISUAL I (A) and VISUAL II (B). GCP = Good Clinical Practice.
*Includes participants who experienced treatment failure, reached 80 weeks of treatment without treatment failure, or had to terminate
the study because the planned number of treatment failures was reached.
†Some participants had multiple reasons for discontinuation; total counts for reasons for discontinuation exceed the total number of
discontinuations.
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Hierarchical testing of the ranked secondary out-
comes showed no statistically signiﬁcant differences
for the ranked secondary endpoints. Similar to
VISUAL I, exploratory analyses on 1–3 secondary end-
points were carried out for hypothesis-generating pur-
poses and showed that all the results favored
adalimumab-treated eyes. The Japan substudy had
similar directionality as the main study (Table 5).
Safety
VISUAL I
The incidence of AEs was comparable between treat-
ment groups (placebo, 960 E/100 PY; adalimumab,
1063 E/100 PY) in the VISUAL I safety analysis set
(Table 6). Serious AEs were reported at rates of
12.7 E/100 PY in the placebo group and 29.5 E/100
PY in the adalimumab group. The most frequently
reported AE was injection site reaction (placebo, 14.8
E/100 PY; adalimumab, 43.5 E/100 PY). Serious infec-
tions occurred at a similar rate between groups. Two
malignancies (one event each of carcinoid tumor of the
gastrointestinal tract and glioblastoma multiforme) and
one event each of active and latent tuberculosis were
reported in the adalimumab group. One participant
with intermediate uveitis in the adalimumab group
reported demyelinating disorder. One event of lupus
or lupus-like reaction was reported in the adalimumab
group. Four participants (3.3%) in the placebo group
and 11 (9.2%) in the adalimumab group discontinued
study drug due to AEs. One death due to end-stage
chronic renal disease was reported in the adalimumab
group. Four participants (3.4%, n = 4/118) had anti-
adalimumab antibodies (AAA+) during the study. The
four AAA+ participants experienced treatment failure at
16, 20, 44, and 48 weeks, respectively; median time to
treatment failure was 21 weeks in AAA– participants
(n = 114).
VISUAL II
The incidence of AEs was comparable between treat-
ment groups (placebo, 884 E/100 PY; adalimumab, 854
E/100 PY) in the VISUAL II safety analysis set
(Table 6). Serious AEs were reported at rates of 14.8
E/100 PY in the placebo group and 13.6 E/100 PY in
the adalimumab group. The most frequently reported
AEs were injection site reactions (placebo, 21.5 E/100
PY; adalimumab, 36.0 E/100 PY). Serious infections
occurred at a similar rate between groups. One death
due to two AEs of aortic dissection and cardiac tam-
ponade leading to death was reported in the adalimu-
mab group. Two malignancies (one event each of non-
serious squamous cell carcinoma of skin and serious
lung adenocarcinoma Stage IV) in the adalimumab
group and one and three events each of latent
FIGURE 1. (Continued).
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tuberculosis were reported in the placebo and adali-
mumab groups, respectively. No lupus or lupus-like
reaction or demyelinating disorders were reported.
Seven participants (5.4%) in the placebo group and
TABLE 4. Primary endpoint for main study, integrated study, and Japan substudy for VISUAL I and VISUAL II trials.
Treatment (N)
Comparison Adalimumab to Placebo
Hazard Ratio* 95% CI p-value†
VISUAL I
Main study (ex-Japan)13 Placebo (n = 107) 0.50 0.36–0.70 <0.001
Adalimumab (n = 110)
Integrated study Placebo (n = 115) 0.56‡ 0.40–0.76 <0.001
Adalimumab (n = 118)
Japan substudy Placebo (n = 8) 1.20 0.41–3.54 NC
Adalimumab (n = 8)
Japan substudy
(excluding the outlier participant)
Placebo (n = 7) 0.73 0.22–2.40 NC
Adalimumab (n = 8)
VISUAL II
Main study (ex-Japan)14 Placebo (n = 111) 0.57 0.39–0.84 0.004
Adalimumab (n = 115)
Integrated study Placebo (n = 127) 0.52‡ 0.37–0.74 <0.001
Adalimumab (n = 131)
Japan substudy Placebo (n = 16) 0.45 0.20–1.03 NC
Adalimumab (n = 16)
NC = not calculated.
*Cox proportional hazards model with treatment as factor.
†Two-sided p-value from log rank test.
‡Cox proportional hazards model with treatment and Japanese race as factors.
TABLE 5. Summary of ranked secondary efﬁcacy variables*.
Difference
(Mean) 95% CI p-value
VISUAL I
1. Change in AC cell grade
Integrated study –0.25 –0.46, –0.04 0.019†
Japan substudy 0.22 –0.17, 0.61 NC
Japan substudy (excluding the outlier participant) 0.20 –0.22, 0.62 NC
2. Change in VH grade
Integrated study –0.28 –0.43, –0.12 < 0.001†
Japan substudy –0.41 –1.15, 0.34 NC
Japan substudy (excluding the outlier participant) –0.58 –1.28, 0.12 NC
3. Change in logMAR BCVA
Integrated study –0.06 –0.10, –0.02 0.008†
Japan substudy 0.04 –0.22, 0.31 NC
Japan substudy (excluding the outlier participant) –0.03 –0.26, 0.21 NC
VISUAL II
1. Change in AC cell grade
Integrated study –0.15 –0.36, 0.06 0.164†
Japan substudy –0.22 –0.90, 0.46 NC
2. Change in VH grade
Integrated study –0.17 –0.31, −0.03 0.016†
Japan substudy –0.45 –0.98, 0.07 NC
3. Change in logMAR BCVA
Integrated study –0.04 –0.09, 0.00 0.044†
Japan substudy –0.08 –0.20, 0.04 NC
AC = anterior chamber; BCVA = best corrected visual acuity; NC = not calculated; VH = vitreous haze.
*Data reﬂect change from best state achieved prior to week 6 to the ﬁnal/early termination visit for VISUAL I and change from
baseline to ﬁnal/early termination visit for VISUAL II.
†From analysis of variance with treatment and Japan vs ex-Japan as factors adjusted for clustered observations.
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11 (8.4%) in the adalimumab group discontinued
study drug due to AEs. Eight participants (6.1%,
n = 8/131) had anti-adalimumab antibodies (AAA+)
during the study. Six out of eight AAA+ participants
experienced treatment failure at 10, 13, 16, 16, 24, and
31 weeks, respectively; median time to treatment fail-
ure was not estimable for AAA– participants, as more
than half of the AAA– participants did not experience
treatment failure (n = 123).
In both Japan substudies, adalimumab was gen-
erally safe and well tolerated, and the AE proﬁle
was consistent with the safety proﬁle established
across other approved indications. No new safety
signals were identiﬁed. Furthermore, AE rates for
the global VISUAL I and VISUAL II trials were
comparable with the respective Japan substudy
(Table 6).
DISCUSSION
In both VISUAL I and VISUAL II integrated data sets,
treatment with adalimumab effectively reduced the risk
of treatment failure compared with placebo in partici-
pants with both active and controlled uveitis. Both clin-
ical trials had a similar but unique study design, large
study population, range of uveitis diagnoses, and a
comprehensive stringent, multi-component primary
endpoint. In both studies, participants receiving adali-
mumab were signiﬁcantly less likely to experience
treatment failure and had fewer reasons for treatment
failure compared with participants receiving placebo.
The median time to treatment failure for adalimumab
was 60% and 87% longer for the integrated population
and main study populations when compared with their
respective placebo populations for the VISUAL I trial.
In VISUAL I, among Japanese participants (n = 16),
time to treatment failurewas shorter than themain study
participants, and there was no clear difference between
the adalimumab group and the placebo group. The
potential explanation for such rapid time to treatment
failure is that the majority of the participants in the Japan
substudy were diagnosed with panuveitis17,18 (13/16
[81.3%]), including all participants in the placebo
group, compared with 97/217 (44.7%) in the main
study. This difference between the uveitis types in two
populations is statistically signiﬁcant and clinically
meaningful. In the main study, among participants
with panuveitis, intermediate, or posterior uveitis receiv-
ing placebo, the rates of treatment failure were 100%,
84%, and 69%, respectively, bymonth 9.Despite the clear
risk reduction of treatment failure in the panuveitis sub-
population receiving adalimumab in the main studies
(VISUAL I: HR = 0.45, p < 0.001; VISUAL II: HR = 0.44,
p = 0.003), participants with panuveitis trended toward
earlier treatment failure comparedwith other anatomical
locations, which may explain why the Japan substudy
had shorter time to treatment failure than themain study
population. Additionally, when compared with the
panuveitis population from the main study (median
time to treatment failure: placebo, 2.9 months and adali-
mumab, 3.8 months), the Kaplan-Meier curves for time
to treatment failure were similar to the Japanese partici-
pants (median time to treatment failure: placebo,
2.8 months and adalimumab, 4.6 months).
Additionally, in the Japan substudy, one participant in
the placebo group did not reach treatment failure during
the maximum double-masked treatment period of
TABLE 6. Summary of adverse events (safety population).
VISUAL I VISUAL II
AEs, Events (Events per 100 PY)
Placebo
(n = 120, PYs = 47.4)
Adalimumab
(n = 119, PYs = 64.4)
Placebo
(n = 130, PYs = 74.4)
Adalimumab
(n = 131, PYs = 102.9)
Any AE 455 (960) 685 (1063) 658 (884) 879 (854)
Serious AE 6 (12.7) 19 (29.5) 11 (14.8) 14 (13.6)
AE leading to discontinuation 5 (10.6) 13 (20.2) 7 (9.4) 12 (11.7)
Serious infections 3 (6.3) 5 (7.8) 2 (2.7) 3 (2.9)
Malignancy 0 2 (3.1)* 0 2 (1.9)†
AE leading to death 0 1 (1.6)‡ 0 2 (1.9)§
Any active TB 0 1 (1.6) 0 0
Any latent TB 0 1 (1.6) 1 (1.3) 3 (2.9)
Any demyelinating disease 0 1 (1.6) 0 0
Injection site reactions 7 (14.8) 28 (43.5) 16 (21.5) 37 (36.0)
ADA = adalimumab; AE = adverse event; PY = participant-year; TB = tuberculosis.
*One event each of carcinoid tumor of the gastrointestinal tract (day 244; resolved on day 251; ADA treatment was not interrupted)
and glioblastoma multiforme (day 242; ADA was discontinued due to this event; last ADA dose, day 248).
†One event each of non-serious squamous cell carcinoma of skin (day 210; resolved on day 215; ADA treatment was not interrupted)
and lung adenocarcinoma Stage IV (day 274; 14 days after last ADA dose; ADA treatment was not interrupted).
‡One death due to end-stage chronic renal disease (37 days after baseline).
§One death due to 2 fatal AEs of aortic dissection and cardiac tamponade (18 days after last ADA dose), not related to ADA
treatment.
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80 weeks. This participant was conﬁrmed as an outlier
with Smirnov-Grubbs’ test. This one outlier out of the
eight participants in the placebo group strongly impacted
the outcome of the study. The HR in the Japan substudy
for the primary endpoint was 0.73 when excluding this
participant. This is a similar directionality to the main
study (0.50) and integrated study (0.56) results. Given
the small sample size of 16 participants, this single outlier
participant drove the result of this substudy. In the
VISUAL II Japan substudy (n = 32), a trend was observed
between the adalimumab and placebo groups in favor of
adalimumab (HR = 0.45). The median time to treatment
failure for the integrated study was not estimable for the
adalimumab group, as fewer than half of patients receiv-
ing adalimumab in the main study experienced treatment
failure, but was signiﬁcantly longer for adalimumab
(> 18 months) compared with placebo (5.6 months). In
the Japan subpopulation, median time to treatment fail-
ure was longer in patients receiving adalimumab
(2.9 months) compared with those receiving placebo
(2.1 months). No clear differences were expected within
the Japan subpopulation, given the small sample sizes of
16 (VISUAL I) and 32 (VISUAL II) participants. The dis-
tribution of speciﬁc etiologies in Japan differed from that
of the overall populations in the VISUAL I and VISUAL II
studies, with sarcoidosis occurring as the most frequently
identiﬁed diagnosis in VISUAL I after idiopathic, and
Vogt Koyanagi Harada and sarcoidosis as the most fre-
quent in VISUAL II.17,18 Despite the small sample size in
the Japan substudies, the higher incidence of sarcoidosis
observed in these studies agrees with the reported inci-
dence in previous Japanese epidemiological studies.17
The trend toward shorter time to treatment failure in the
Japan substudy emphasizes the importance of character-
izing geographical differences in uveitis diagnostic fre-
quencies, which may be correlated with environmental
and other exogenous factors.18 As mentioned, these ﬁnd-
ings should be interpreted with caution due to the small
size for each treatment group, particularly in VISUAL I
(n = 8 per group).
The efﬁcacy results for these controlled trials are
supported by previous uncontrolled studies. In a retro-
spective study in participants with refractory chronic
uveitis, adalimumab effectively controlled inﬂamma-
tion in 35% of participants who were refractory to
previous treatment with inﬂiximab or etanercept.19 In
a prospective open-label pilot study of 19 participants
with active intraocular inﬂammation treated with ada-
limumab, 33 eyes (86%) had cystoid macular edema by
optical coherence tomography at baseline. After 1 year
of treatment visual acuity improved by −0.3 logMAR
in 12/38 (31%) eyes, inﬂammation was signiﬁcantly
reduced in 63% of participants, and cystoid macular
edema completely resolved in 55%.20 In a multicenter
study of 131 participants with a mean age of 27 years,
adalimumab therapy signiﬁcantly improved anterior
chamber and vitreous inﬂammation, and it was
possible to taper CS.21 In another non-comparative
open-label prospective study of 31 participants with
refractory uveitis, 68% of participants were clinical
responders at 10 weeks, and sustained response at
50 weeks was seen in 39% of the participants.22 The
French uveitis network recently published a multicen-
ter study of 160 participants with refractory uveitis
treated with anti-TNFα (inﬂiximab and adalimumab)
agents. The participants had an overall response rate
of 93% at 12 months.23 Most recently, the main study
data from VISUAL I and VISUAL II studies also
demonstrated the efﬁcacy and safety of adalimumab
(anti-TNFα) to treat uveitis.13,14
Low adalimumab immunogenicity was observed in
both VISUAL I and VISUAL II studies and was in the
range of rates observed in other disease states.13,14 The
safety proﬁle of adalimumab was similar to the estab-
lished safety proﬁle for approved adalimumab
indications,24 and the rates of AEs were similar com-
pared with placebo. In participants with active uveitis
(VISUAL I), the overall rates of adalimumab-asso-
ciated AEs were higher than the placebo group, as
were serious AEs and AEs leading to discontinuation.
In participants with inactive uveitis (VISUAL II), injec-
tion-site reactions were the most frequently reported
AEs with adalimumab, consistent with other reports.-
21,25 The strengths and the limitations of the VISUAL I
and VISUAL II studies have been described and
published.13,14 Additionally, in the Japan substudies,
the sample sizes of 16 participants (VISUAL I) and 32
participants (VISUAL II) were very low and no clear
differences were expected. Furthermore, to receive
60 mg of prednisone per the VISUAL I protocol, parti-
cipants needed to be hospitalized, which was one of
the reasons for low enrollment in the VISUAL I study
in Japan.
In conclusion, adalimumab lowered the risk of uveitic
ﬂare or visual acuity loss in participants with active and
controlled uveitis who are at risk of the long-term side
effects of CS. Based on results taken together from
VISUAL I and VISUAL II trials, there is no reason to
believe that adalimumab treatment in Japanese partici-
pants with non-infectious uveitis would have different
effects from those in non-Japanese participants. Safety
data from the two studies in Japanese and non-Japanese
populations are consistent with the safety proﬁle estab-
lished across other approved indications. On the basis of
the results from the VISUAL studies, adalimumab
received approvals from the FDA, EMA, and Japan
PMDA, and is the ﬁrst non-CS biologic to be licensed
for the treatment of non-infectious uveitis.14,23
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